- Home
- ERIE vs RPRX Comparison
ERIE vs RPRX Comparison
Compare ERIE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERIE | RPRX |
|---|---|---|
| Founded | 1925 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 16.4B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ERIE | RPRX |
|---|---|---|
| Price | $284.63 | $40.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $45.75 |
| AVG Volume (30 Days) | 180.3K | ★ 3.5M |
| Earning Date | 10-30-2025 | 02-10-2026 |
| Dividend Yield | 2.08% | ★ 2.22% |
| EPS Growth | ★ 15.90 | N/A |
| EPS | ★ 12.39 | 1.75 |
| Revenue | ★ $4,040,325,000.00 | $2,349,844,000.00 |
| Revenue This Year | $9.98 | $37.66 |
| Revenue Next Year | $5.75 | $2.34 |
| P/E Ratio | $22.75 | ★ $22.64 |
| Revenue Growth | ★ 9.53 | 3.70 |
| 52 Week Low | $273.59 | $25.40 |
| 52 Week High | $456.93 | $41.24 |
Technical Indicators
Market Signals| Indicator | ERIE | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 66.65 |
| Support Level | $275.82 | $38.29 |
| Resistance Level | $289.66 | $39.46 |
| Average True Range (ATR) | 5.89 | 0.65 |
| MACD | 0.31 | 0.12 |
| Stochastic Oscillator | 58.76 | 89.30 |
Price Performance
Historical ComparisonAbout ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.